← Leaderboards
Scott Tashman
Henry Ford Health System
$4,660,160
Attributed
$8,906,275
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $790.3K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,906,275 · 6
By mechanism
R01$5,488,706 · 3
UH3$2,563,053 · 1
UG3$522,288 · 1
R21$332,228 · 1
Top collaborators
- Johnny Huard8 shared
- Marc Philippon6 shared
- James John Irrgang5 shared
- Freddie H Fu3 shared
- Richard E Debski2 shared
- Vihang A Narkar2 shared
Most similar at Henry Ford Health System
Same institution · by research overlap
- Yener N Yeni$2,085,514
Others in their field
Top investigators on “Operative Surgical Procedures”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Larry Arthur$195,389,208
- Norman Wolmark · Nsabp Foundation, Inc.$177,775,854
- Lawrence Corey · Fred Hutchinson Cancer Center$130,508,383
- Richard K. Wilson · Washington University$128,382,063
Research focus
Operative Surgical ProceduresDegenerative PolyarthritisDesignMotionInjuryJointsKinematicsKneeCartilageBaseStructurePreventMagnetic Resonance ImagingTissuesImproved OutcomeRepairedGrantResearch PersonnelRandomizedProspectiveRandomized Clinical TrialsKnee OsteoarthritisKnee JointAnterior Cruciate Ligament
Grant awards (23)
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$551,586
UH3 · FY2024 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$600,051
UH3 · FY2023 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$621,091
UH3 · FY2022 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$633,825
UH3 · FY2021 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$156,500
UH3 · FY2021 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$522,288
UG3 · FY2020 · AR
Development of biological approaches to enhance skeletal muscle rehabilitation after anterior cruciate ligament injury$143,688
R21 · FY2020 · AR
Development of biological approaches to enhance skeletal muscle rehabilitation after anterior cruciate ligament injury$188,540
R21 · FY2019 · AR
Predicting the Outcome of Exercise Therapy for Treatment of Rotator Cuff Tears$634,755
R01 · FY2017 · AR
Predicting the Outcome of Exercise Therapy for Treatment of Rotator Cuff Tears$628,976
R01 · FY2016 · AR
Single- vs. Double-Bundle ACL Reconstruction: A Prospective Randomized Trial$584,396
R01 · FY2012 · AR
Single- vs. Double-Bundle ACL Reconstruction: A Prospective Randomized Trial$535,818
R01 · FY2011 · AR
Single- vs. Double-Bundle ACL Reconstruction: A Prospective Randomized Trial$567,659
R01 · FY2010 · AR
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$298,253
R01 · FY2009 · AR · contact PI
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$160,000
R01 · FY2009 · AR · contact PI
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$298,293
R01 · FY2008 · AR · contact PI
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$304,226
R01 · FY2007 · AR · contact PI
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$325,118
R01 · FY2006 · AR · contact PI
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$316,800
R01 · FY2005 · AR
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$189,342
R01 · FY2003 · AR
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$200,402
R01 · FY2002 · AR
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$227,991
R01 · FY2001 · AR
DYNAMIC KNEE STABILITY AFTER ACL RECONSTRUCTION$216,677
R01 · FY2000 · AR